The project will be conducted using 3 research platforms, the first being a clinical trial platform led by BNITM and CERMEL (WP 2) with:

• the pilot study in Gabon. This is a mono-centre study to investigate tolerability and safety issues of the tri-therapy ASAQ+AP in an adolescent and adult population,
• the main study which is a blinded multi-centre clinical phase III study to evaluate the safety, tolerability, and efficacy of ASAQ+AP for the treatment of uncomplicated falciparum malaria in African children from 6 months to 10 years.
• and the pharmacokinetics/pharmacodynamics of the antimalarials drugs in children under five years old.